GleamWall
中文EN

NUMD Nu-Med Plus, Inc.

Gold and Silver Ores · OTC · SEC CIK 1543637 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY17.8%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-650.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets3,529.1%
Debt / equity—
Current ratio0.03x
Interest coverage-6.77x

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-94.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
SG&A expense$23,115$34,324
Operating income-$48,955-$63,331
Interest expense$7,227$5,014
Pretax income-$56,182-$68,345
Net income-$56,182-$68,345
EBITDA-$48,955-$63,331
EPS (basic)0.000.00
EPS (diluted)0.000.00
Weighted avg. shares (diluted)83.55M83.55M
Balance sheet
Cash & equivalents$661$2,373
Current assets$7,911$9,373
PP&E, net$0—
Total assets$7,911$9,373
Current liabilities$279,189$224,469
Long-term debt$0—
Total debt$0—
Total liabilities$279,189$224,469
Shareholders' equity-$271,278-$215,096
Net debt-$661—
Shares outstanding83.55M83.55M
Cash flow statement
Operating cash flow-$47,979-$4,433
Financing cash flow$46,267—
Depreciation & amortization$0$0

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.